These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 33906204)

  • 1. A core outcome set for vasomotor symptoms associated with menopause: the COMMA (Core Outcomes in Menopause) global initiative.
    Lensen S; Archer D; Bell RJ; Carpenter JS; Christmas M; Davis SR; Giblin K; Goldstein SR; Hillard T; Hunter MS; Iliodromiti S; Jaisamrarn U; Joffe H; Khandelwal S; Kiesel L; Kim BV; Lambalk CB; Lumsden MA; Maki PM; Nappi RE; Panay N; Roberts H; Shifren J; Simon JA; Vincent A; Wolfman W; Hickey M
    Menopause; 2021 Apr; 28(8):852-858. PubMed ID: 33906204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A core outcome set for genitourinary symptoms associated with menopause: the COMMA (Core Outcomes in Menopause) global initiative.
    Lensen S; Bell RJ; Carpenter JS; Christmas M; Davis SR; Giblin K; Goldstein SR; Hillard T; Hunter MS; Iliodromiti S; Jaisamrarn U; Khandelwal S; Kiesel L; Kim BV; Lumsden MA; Maki PM; Mitchell CM; Nappi RE; Niederberger C; Panay N; Roberts H; Shifren J; Simon JA; Stute P; Vincent A; Wolfman W; Hickey M
    Menopause; 2021 May; 28(8):859-866. PubMed ID: 33973541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protocol for development of a core outcome set for menopausal symptoms (COMMA).
    Kim BV; Iliodromiti S; Christmas M; Bell R; Lensen S; Hickey M;
    Menopause; 2020 Dec; 27(12):1371-1375. PubMed ID: 32898018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of women's treatment preferences for vasomotor symptoms due to menopause.
    Shiozawa A; Thurston RC; Cook E; Yang H; King DD; Kristy RM; Mancuso S
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(10):1117-1128. PubMed ID: 37650213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasomotor symptom characteristics: are they risk factors for incident diabetes?
    Gray KE; Katon JG; LeBlanc ES; Woods NF; Bastian LA; Reiber GE; Weitlauf JC; Nelson KM; LaCroix AZ
    Menopause; 2018 May; 25(5):520-530. PubMed ID: 29206771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlations among Core Outcomes in Menopause-recommended vasomotor symptom outcomes in MsFLASH trials.
    Carpenter JS; Larson JC; Hunter MS; Lensen S; Chen CX; Guthrie KA
    Menopause; 2024 Jan; 31(1):3-9. PubMed ID: 37963308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of nulliparity, hypertensive disorders of pregnancy, and gestational diabetes on vasomotor symptoms in midlife women.
    Cortés YI; Conant R; Catov JM; Matthews KA; Crawford SL; Hedderson MM; Thurston RC
    Menopause; 2020 Dec; 27(12):1363-1370. PubMed ID: 32796290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The severity of vasomotor symptoms and number of menopausal symptoms in postmenopausal women and select clinical health outcomes in the Women's Health Initiative Calcium and Vitamin D randomized clinical trial.
    Nudy M; Jiang X; Aragaki AK; Manson JE; Shadyab AH; Foy AJ; Buerger J; Kelsey AM; LeBlanc ES; Wild RA; Wactawski-Wende J; Stefanick ML; Robbins JA; Schnatz PF
    Menopause; 2020 Nov; 27(11):1265-1273. PubMed ID: 33110042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of fezolinetant in alleviating vasomotor symptoms linked to Menopause.: A systematic review and Meta-Analysis.
    Elnaga AAA; Alsaied MA; Elettreby AM; Ramadan A
    Eur J Obstet Gynecol Reprod Biol; 2024 Jun; 297():142-152. PubMed ID: 38640780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommended measurement instruments for menopausal vasomotor symptoms: the COMMA (Core Outcomes in Menopause) consortium.
    Lensen S; Paramanandam VS; Gabes M; Kann G; Donhauser T; Waters NF; Li AD; Peate M; Susanto NS; Caughey LE; Rangoonwal F; Liu J; Condron P; Anagnostis P; Archer DF; Avis NE; Bell RJ; Carpenter JS; Chedraui P; Christmas M; Davies M; Hillard T; Hunter MS; Iliodromiti S; Jaff NG; Jaisamrarn U; Joffe H; Khandelwal S; Kiesel L; Maki PM; Mishra GD; Nappi RE; Panay N; Pines A; Roberts H; Rozenberg S; Rueda C; Shifren J; Simon JA; Simpson P; Siregar MFG; Stute P; Garcia JT; Vincent AJ; Wolfman W; Hickey M
    Menopause; 2024 Jul; 31(7):582-590. PubMed ID: 38688464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment strategies for reducing the burden of menopause-associated vasomotor symptoms.
    Umland EM
    J Manag Care Pharm; 2008 Apr; 14(3 Suppl):14-9. PubMed ID: 18439062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variation in menopausal vasomotor symptoms outcomes in clinical trials: a systematic review.
    Iliodromiti S; Wang W; Lumsden MA; Hunter MS; Bell R; Mishra G; Hickey M
    BJOG; 2020 Feb; 127(3):320-333. PubMed ID: 31621155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships Between Vasomotor Symptoms and Mood in Midlife Urban Chinese Women: Observations in a Prospective Study.
    Tang R; Luo M; Li J; Peng Y; Wang Y; Liu B; Liu G; Wang Y; Lin S; Chen R
    J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32841324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause.
    Fraser GL; Lederman S; Waldbaum A; Kroll R; Santoro N; Lee M; Skillern L; Ramael S
    Menopause; 2020 Apr; 27(4):382-392. PubMed ID: 32102086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and quality-of-life burden of vasomotor symptoms associated with menopause: A European cross-sectional survey.
    Nappi RE; Siddiqui E; Todorova L; Rea C; Gemmen E; Schultz NM
    Maturitas; 2023 Jan; 167():66-74. PubMed ID: 36306669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variation in outcome reporting and measurement tools in clinical trials of treatments for genitourinary symptoms in peri- and postmenopausal women: a systematic review.
    Christmas MM; Song B; Bell RJ; Iliodromiti S; Mitchell C; Hickey M;
    Menopause; 2020 Sep; 27(9):1070-1080. PubMed ID: 32852462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and severity of vasomotor symptoms and joint pain in women at midlife in Bangladesh: a population-based survey.
    Islam RM; Bell RJ; Billah B; Hossain MB; Davis SR
    Menopause; 2016 Jul; 23(7):731-9. PubMed ID: 26926325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a pilot study of a cooling mattress pad to reduce vasomotor symptoms and improve sleep.
    Avis NE; Levine BJ; Coeytaux R
    Menopause; 2022 Aug; 29(8):973-978. PubMed ID: 35881974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasomotor Symptoms and Accelerated Epigenetic Aging in the Women's Health Initiative (WHI).
    Thurston RC; Carroll JE; Levine M; Chang Y; Crandall C; Manson JE; Pal L; Hou L; Shadyab AH; Horvath S
    J Clin Endocrinol Metab; 2020 Apr; 105(4):1221-7. PubMed ID: 32080740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial.
    Joffe H; Guthrie KA; LaCroix AZ; Reed SD; Ensrud KE; Manson JE; Newton KM; Freeman EW; Anderson GL; Larson JC; Hunt J; Shifren J; Rexrode KM; Caan B; Sternfeld B; Carpenter JS; Cohen L
    JAMA Intern Med; 2014 Jul; 174(7):1058-66. PubMed ID: 24861828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.